Logomix, Inc., a Tokyo-based mammalian synthetic biology company developing artificial human cells for new therapeutics based on its pioneering Geno-Writing™ platform technology. Geno-Writing™ is Logomix’s innovative genome engineering platform to write large-scale and complex messages into a genome. It will enable therapy developers to write therapeutics sequences to develop new modalities and cure serious diseases such as cancer, neurodegenerative diseases, and genetic diseases under discovery collaborations with biopharma companies.